Posts by Selector

CGC/TWEED

Ich habe heute zwei Nachrichten. Eine finde ich gut, die andere finde ich für mich nicht so beruhigend.

Nun, dies ist die gute Nachricht:

SMITHS FALLS, ON, May 14, 2018 /CNW/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) is pleased to announce that it has entered into a non-binding agreement (the "Agreement") to purchase, subject to certain conditions, the remaining 33% stake of BC Tweed Joint Venture Inc. ("BC Tweed") not currently owned by the Company. The consolidation of the two largest licensed cannabis facilities in the world into full Canopy Growth ownership cements the Company's commitment to shareholder value through scale production.

Canopy Growth, upon closing of the transaction, will issue up to $374 million worth of shares in the Company, subject to the satisfaction of certain conditions, to the minority shareholders of BC Tweed (the "Operators"). Payments are milestone-based and will be released over four years based upon the achievement of certain production milestones. The Operators, multi-generational cultivators, will continue to manage the BC-based operations for a period of 5 years.

The BC Tweed greenhouses represent a meaningful share of the entire Canadian production landscape with up to 3 million square feet of greenhouse growing capacity. Since the formation of BC Tweed in October of 2017, already over 1.7 million square feet has been licensed for production to meet to oncoming recreational cannabis demand across the country.

"Our provincial distribution agreements, commitment to quality and value-add processing, and leading brand portfolio position Canopy Growth as the market share leader in Canada's future recreational cannabis market," said Bruce Linton, Chairman & CEO, Canopy Growth. "Consolidating BC Tweed fully under the Canopy ensures that the full value of our strategic position is realized by Canopy shareholders."

Under the terms of the Agreement, subject to approval of the Toronto Stock Exchange and certain other conditions, the Company will issue $374 million worth of common shares in the capital of the Company based on the volume weighted average price per common share for the 20 trading day period ended May 11, 2018 (the "VWAP"). The Company will also pay $1 million in cash as a non-refundable deposit against the purchase price. In addition, the Company will issue $20 million worth of common shares in the capital of the Company at the same VWAP in connection with an option to acquire certain future infrastructure from the Operators, subject to certain conditions. The transaction is anticipated to close in early July, following the negotiation of definitive agreements.

Und diese hier, naja, ist Vertrauenssache, finde ich.- *dirol*

SMITHS FALLS, ON, May 14, 2018 /CNW/ - Canopy Growth Corporation ("Canopy Growth" or the "Company")(TSX: WEED) announced today it has applied to list its common shares on the New York Stock Exchange (the "NYSE").

The Company currently anticipates that, subject to the receipt of all required approvals, its common shares will begin trading on the NYSE before the end of May 2018. In advance of listing on the NYSE, Canopy Growth will file a Form 40-F Registration Statement with the United States Securities and Exchange Commission. The listing of the Company's common shares on the NYSE remains subject to the approval of the NYSE and the satisfaction of all applicable listing and regulatory requirements.

Canopy Growth's common shares will trade on the NYSE under the ticker symbol "CGC" and will continue to trade on the TSX under the ticker symbol "WEED". A trading date will be made public once all regulatory formalities are satisfied.

In announcing the application to list on a U.S. stock exchange, Canopy Growth's Chairman & CEO, Bruce Linton, commented: "Since becoming the first regulated cannabis producer to list their shares in North America in 2014 our team has focused on building credibility through consistent execution. Once finalized, listing our shares on the NYSE will represent a continuation of our upward trajectory as we build the global cannabis industry."

Aktuell

Heute bin ich mal mit aktuellen und erfreulichen News dabei:

https://www.newswire.ca/news-r…government-680869711.html

SMITHS FALLS, ON and MELBOURNE, Australia, April 25, 2018 /CNW/ - Canopy Growth Corporation (TSX: WEED) ("Canopy Growth" or the "Company") is pleased to join the Victoria State Government in announcing the launch of the newest member of the Canopy Growth family, Spectrum Cannabis Australia ("Spectrum" or "Spectrum Australia").

Minister for Agriculture, the Hon. Jaala Pulford, alongside Ben Quirin, Managing Director of Spectrum Australia, announced the Company will invest up to $16 million AUD (~$16 million CAD) in the State of Victoria over the next four years to establish Spectrum's Asia-Pacific (APAC) headquarters and research and development facility.

"The State Government of Victoria has been an outstanding partner and welcomed our investment in the region with a shared passion for innovation in the medical cannabis industry," said Ben Quirin, Managing Director, Spectrum Australia. "Victoria is now home for Spectrum as we introduce our world renowned medical cannabis products to the State, across Australia, and throughout the entire APAC region as jurisdictions establish legal, regulated medical cannabis regimes."

The Victoria facility will enable domestic cultivation and production of high quality medical cannabis for patients while serving as a distribution hub for other jurisdictions in APAC. It will also operate as the APAC Research and Development Center for the Company, supporting the ongoing research collaboration between Spectrum Australia and Agriculture Victoria on innovations in medical cannabis cultivation and production.

"Collaborating with international experts on cultivation and manufacturing will build Victoria's capacity to develop our medicinal cannabis industry to be able to supply reliable and high quality medicinal cannabis products," said Minister for Agriculture, the Hon. Jaala Pulford.

The launch of Spectrum Australia builds on Canopy Growth's leadership position in the global medical cannabis space. Spectrum Australia's priority is to improve the lives of patients. This goal will be accomplished by focusing on three core areas:

1. Ensuring an affordable and consistent supply of medical cannabis is available to patients in Australia
2. Building production and research infrastructure in Australia
3. Engaging in rigorous evidence-based physician and pharmacist education to ensure patients' access needs are met

This week Canopy Growth renewed its commitment to Australian partner, AusCann (ASX:AC8). Together with the State Government of Victoria and our strong local partner Spectrum Australia is committed to building an industry for the benefit of patients and healthcare professionals throughout APAC.

Spectrum Cannabis - Medical Cannabis. Simplified.

Learn more by visiting spectrumcannabis.com.au

About Spectrum Cannabis

Spectrum is an international cannabis business dedicated to improving the lives of patients and increasing cannabinoid knowledge within physician communities around the world. Its colour-coded strain classification system is available in Canada with operations underway in the European Union and South America, and Australia. Spectrum products are available in a range of potencies and formats designed to simplify the dialogue around strength and dosage by categorizing medical cannabis according to THC and CBD levels. Spektrum Germany Gmbh processes cannabis for sale in Germany in a GMP-certified facility and then distributes products to hundreds of German pharmacies. Spectrum Denmark is a partnership between Canopy Growth and Danish Cannabis. Through the partnership, Spectrum Denmark is developing a large-scale greenhouse facility in the city of Odense. Learn more at www.spectrumcannabis.com.au

About Canopy Growth Corporation

Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time.

Canopy Growth has established partnerships with leading sector names including cannabis icon Snoop Dogg, breeding legends DNA Genetics and Green House seeds, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates eight cannabis production sites with over 2.4 million square feet of production capacity, including over 500,000 square feet of GMP-certified production space. The Company has operations in seven countries across four continents. The Company is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public's understanding of cannabis, and through its partly owned subsidiary, Canopy Health Innovations, has devoted millions of dollars toward cutting edge, commercializable research and IP development. Through partly owned subsidiary Canopy Rivers Corporation, the Company is providing resources and investment to new market entrants and building a portfolio of stable investments in the sector. From our historic public listing to our continued international expansion, pride in advancing shareholder value through leadership is engrained in all we do at Canopy Growth. For more information visit www.canopygrowth.com.

FSLR

Nun gehen sie aber hoch! *dirol*

https://www.barrons.com/articl…t-solar-shines-1524057347

https://seekingalpha.com/news/…od-news-upgraded-buy-baml

First Solar 'could surge on good news,' upgraded to Buy at BAML

Apr. 18, 2018 7:55 AM ET|By: Carl Surran, SA News Editor

First Solar (NASDAQ:FSLR) +3.2% premarket after BofA Merrill Lynch upgrades shares to Buy from Neutral with an $83 price target, raised from $75, saying "shares have been stuck but could surge on good news."

BAML's Julien Dumoulin-Smith sees Chinese solar demand growing in 2018, “holding up the global panel pricing environment yet again," as well as a draft and potential release of safe harbor language for construction latitude around the Solar Investment Tax Credit bringing “long-term stability to solar deployments."

“Import tariff exemptions appear less likely, also firming domestic pricing," Dumoulin-Smith writes.

See all stocks on the move »

Now read: Time To Move To Sidelines On First Solar »

Neue Parterschaften

Ja Petra, das weiss man dort eben nie so genau...

https://www.newswire.ca/news-r…is-medical-679801443.html

16.04.2018 | 14:13

Smiths Falls, Ontario und Prag, Tschechische Republik (ots/PRNewswire) -

Canopy Growth Corporation (TSX: WEED) ("Canopy Growth" oder das "Unternehmen") freut sich anzukündigen, dass das Unternehmen endgültige Verträge zur Übernahme von Annabis Medical s.r.o ("Annabis Medical") unterzeichnet hat und damit den Fokus des Unternehmens in einen weiteren aufstrebenden Markt für medizinisches Cannabis erweitern wird. Dieses Geschäft soll am Montag, dem 16. April 2018 zum Abschluss gebracht werden.

Annabis Medical ist in der Tschechischen Republik Branchenführer für medizinisches Cannabis und importiert und vertreibt derzeit Cannabis-Produkte für den Verkauf über den Apotheken-Vertriebskanal im Rahmen tschechischer Lizenzen in der Tschechischen Republik. Sein Gründer und CEO, Dr. Robin Kazík, wird auch weiterhin das tschechische Tochterunternehmen als Teil der größeren Canopy Growth-Familie leiten und voranbringen.

"Diese Übernahme ist ein weiteres Beispiel für unser Engagement, die Präsenz von Canopy in Europa zu erweitern und unsere Führungsposition auszubauen", sagt Mark Zekulin, President von Canopy Growth. "Wir freuen uns darauf, tschechische Kunden mit unseren hochwertigen medizinischen Cannabis-Produkten aus GMP-Produktion zu beliefern und weitere Ressourcen zur Unterstützung der Weiterbildung tschechischer Apotheker, Patienten und medizinischer Fachkräfte bieten zu können."

Durch die Kombination des weitreichenden globalen Erfahrungsschatzes und Netzwerks mit der starken nationalen Position von Annabis Medical ist Canopy stolz, seine renommierte Marke Spectrum Cannabis auf einen weiteren europäischen Markt zu bringen.

"Mit einer soliden Präsenz und einem etablierten Vertriebsnetz auf dem tschechischen Markt für medizinisches Cannabis, sowie aufgrund der langjährigen Erfahrung beim Import von Cannabis aus Kanada freuen wir uns, zur Canopy Growth-Familie zu stoßen. Dieser Schachzug wird es uns ermöglichen, unser Produktangebot noch schneller zu diversifizieren, und unseren Zugang zu Rohmaterialien stärken, wenn wir im Markt wachsen", sagte Dr. Robin Kazík, Gründer und CEO von Annabis Medical.

Die Übernahme von Annabis Medical baut auf der Führungsposition von Canopy Growth im europäischen Segment für medizinisches Cannabis auf und folgt der kürzlich zustande gekommenen Partnerschaft und dem Liefervertrag mit dem führenden spanischen Pharmaunternehmen Alcaliber S.A. Darüber hinaus beliefert Canopy Growth derzeit schon den deutschen Markt über sein Tochterunternehmen Spektrum Cannabis GmbH und ist eine Partnerschaft mit Spectrum Cannabis Denmark ApS eingegangen, das über eine Lizenz für den Anbau von Cannabis in einer 40.000 Quadratmeter großen Treibhaus-Produktionseinrichtung in Odense, Dänemark, verfügt. Diese Aktiva, in Kombination mit den unvergleichlichen Produktions- und Vertriebsplattformen von Canopy Growth in Kanada, ergeben die am stärksten diversifizierte Cannabis-Plattform der Welt.

Gemäß den Vertragsbestimmungen wird das Unternehmen bei Abschluss 50.735 Stammaktien aus dem Eigenkapital mit einem Wert von CAD 1.491.882,70 an Dr. Kazík ausgeben und wird, vorbehaltlich der Erreichung bestimmter Meilensteine, bis zu 34.758 weitere Stammaktien mit einem Wert von CAD 1.022.080,00 (Basis 5-Tages-VWAP von CAD 29,40519 am 5. April 2018) ausgeben. Der Gesamtwert der im Rahmen des Vertrags zu zahlenden Vergütung beträgt ca. CAD 2.513.962,70. Sämtliche Beträge sind, soweit nicht anderweitig aufgeführt, in Kanadischen Dollar (CAD) angegeben.

Über Annabis Medical s.r.o

Annabis Medical s.r.o ist ein in der Tschechischen Republik ansässiger Lieferant von medizinischem Cannabis und hält seit 2014 entweder unmittelbar oder über Tochtergesellschaften Lizenzen für medizinisches Cannabis. Der Vertrieb von medizinischem Cannabis begann 2015, wobei das Unternehmen schon vorher mit Office of Medicinal Cannabis aus den Niederlanden zusammengearbeitet und zudem medizinisches Cannabis aus Kanada importiert hatte. Das Schwesterunternehmen Annabis, s.r.o. stellt Biokosmetik auf Hanfbasis her und ist nicht in die Transaktion involviert.

Jordan Sinclair, Director of Communications, Jordan@tweed.com, +1-613-769-4196; Investor Relations: Tyler Burns, Tyler.Burns@canopygrowth.com , +1-855-558-9333 ex 122; Director: Bruce Linton, tmx@tweed.com

OTS: Canopy Growth Corporation newsroom: http://www.presseportal.de/nr/121334 newsroom via RSS: http://www.presseportal.de/rss/pm_121334.rss2

© 2018 news aktuell

DELTA, BC, April 14, 2018 /CNW/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) is pleased to announce that yesterday it received additional licensing at both greenhouse facilities operating under its majority-owned BC Tweed Joint Venture banner, including the licensing of the largest cannabis facility in the world.

In particular, the already operating 1.3 million sq. ft. greenhouse facility in Aldergrove, BC, where 400,000 sq. ft. of canopy under glass was licensed in February, is now licensed for 840,000 sq. ft. of growing space.

The second BC Tweed site, totalling 1.7 million sq. ft. of greenhouse production space, also received a cultivation licence for its first 900,000 sq. ft. of growing space.

In total, Canopy Growth's licensed growing space has tripled in calendar 2018, to more than 2.4 million sq. ft. and remains on path to exceed 5.6 million sq. ft. of domestic growing space.

In consultation with IIROC and as a best practice, the Company decided to halt trading of its common shares on the TSX as soon as the licensing news was made public as the increased production capacity represents a material change in operations.

"This is all about focus and execution for our expanding team at Canopy Growth," said Mark Zekulin, President, Canopy Growth. "We have spent four years establishing the largest licensed cannabis production platform in the world. This afternoon with two key licensing milestones, we doubled it."

Want to learn more about our team at BC Tweed: visit us here.
https://www.youtube.com/watch?v=c9qhIX7Kk_c

Here's to Future (BC) Growth (and BC Bud).

About BC Tweed Joint Venture
BC Tweed Joint Venture is a collaboration between Canopy Growth and an established, large-scale greenhouse grower to develop up to 3 million sq. ft. of high-end, automated greenhouse production space across two sites in beautiful British Columbia. Production is already underway to serve the growing demand for Canopy's family of genetics.

CGC / Liefervereinbarung

Heute wieder gute News *smile* *dirol* (war kurz weg, danke für die Info @ Emil)

Presse:

http://www.stockwatch.com/News…aspx?bid=Z-C:WEED-2592370

Canopy Growth completes three year supply agreement with the Société des alcools du Québec

Canada NewsWire

SMITHS FALLS, ON, April 11, 2018

SMITHS FALLS, ON, April 11, 2018 /CNW/ - Canopy Growth Corporation ("Canopy Growth") (TSX: WEED) today announced that it has completed a three year supply agreement with the Société des alcools du Québec ("SAQ") for 12,000 kgs of high-quality cannabis products.

Securing this long term agreement marks another important step in preparing for a legal recreational market in the province of Quebec, and builds upon the letter of intent signed in early February of this year.

"This agreement is an exciting next step in delivering a wide range of our safe, high-quality products to consumers across the province," said Mark Zekulin, President, Canopy Growth. "Quebec is home for Canopy Growth and we're proud to be advancing this long term partnership to develop the Québec market."

Canopy Growth has well-established presence in the province of Québec through its wholly- owned subsidiary Vert Cannabis in Saint Lucien and Vert Mirabel, a company recently formed with Canopy Rivers and Les Serres Stéphane Bertrand Inc., a large-scale greenhouse operator in Mirabel. The 700,000 sq. ft. greenhouse at Vert Mirabel is currently being retrofitted and optimized for cannabis production.

The supply agreement is conditional upon the federal and provincial governments adopting the necessary regulatory framework.

This agreement is a milestone of significance for the Canadian cannabis industry as a whole and accordingly, congratulations are in order for other licensed producers who have completed their first agreements with the SAQ, marking a truly historic day for the sector.

Quelle:

https://web.tmxmoney.com/artic…9085737154&qm_symbol=WEED

Jahres-Zahlen 2017

Starkes Ergebnis, bravo *smile* *dirol*

20-03-2018 13:12

Partners Group steigert 2017 Einnahmen und Gewinn stark - Höhere Dividende

Zürich (awp) - Der Asset Manager Partners Group hat im Geschäftsjahr 2017 die Einnahmen deutlich gesteigert und die Gewinnzahlen noch schneller erhöht. Die Gewinnmarge stieg in der Folge deutlich über die Zielwerte der Gruppe. Das Partners Group-Management verwies vor den Medien allerdings auf günstige Sonderfaktoren im vergangenen Jahr, entsprechend werde sich die Marge künftig wieder zurückbilden. Die Aktionäre profitieren vom guten Ergebnis durch eine kräftige Erhöhung der Dividende um 4 auf 19 CHF.

Die Einnahmen des auf Privatmarktanlagen spezialisierten Asset Managers erhöhten sich im vergangenen Jahr um 28% auf 1,25 Mrd CHF, wie Partners Group am Dienstag mitteilte. Unter dem Strich resultierte ein Reingewinn auf neuer Rekordhöhe von 752 Mio CHF, was einem Anstieg um 35% im Jahresvergleich entsprach.

Das Management versuchte an der Bilanzmedienkonferenz in Zürich, das rasante Wachstum etwas zu relativieren: "Die Ergebnisse waren fast ein wenig zu gut", meinte etwa der abtretende Verwaltungsratspräsident Peter Wuffli.

Weiterhin profitierte die Partners Group im vergangenen Jahr aber von einer starke Kundennachfrage nach ihren Produkten über sämtliche Anlageklassen, wie die Verantwortlichen erklärten. Das Wachstumspotenzial für Privatmarkt-Anlagen sei weiterhin intakt, meinte Co-CEO André Frei. Diese Anlagen versprächen den institutionellen Anlegern nicht nur eine "Outperformance", sondern auch eine Diversifizierung ihrer Asset-Allokation.

STARKE KUNDENNACHFRAGE

Die Management-Gebühren (+29%) stiegen im vergangenen Jahr stärker an als die verwalteten Vermögen, die gemessen in Euro um 14% zulegten. 2017 habe Partners Group zahlreiche Investitionsprogramme geschlossen und dabei "Late Management"-Gebühren generiert, erläuterte Finanzchef Philip Sauer. Bereits das laufende Jahr werde diesbezüglich weniger günstig aussehen: Der Asset Manager lege 2018 neue Programme auf, wobei Management-Gebühren erst zu einem späteren Zeitpunkt anfallen dürften.

Auch beim Wachstum der Performance-Gebühren (+30%) sei man 2017 am oberen Ende der langfristigen Bandbreite (+20 bis +30%) angelangt, betonte der Finanzchef. Die Performance-Gebühren zeigten immer wieder Schwankungen, weil sie typischerweise beim Erreichen gewisser Hürden fällig werden, wie Sauer erklärte.

Der Betriebsgewinn (EBITDA) stieg im vergangenen Jahr gar um 37% auf 825 Mio CHF an. Das starke Gebührenwachstum habe den Mitarbeiteraufbau in der Berichtsperiode übertroffen, hiess es zur Begründung. Die EBITDA-Marge erhöhte sich in der Folge auf 66% (VJ 62%), womit das Unternehmen das eigene Ziel von rund 60% klar übertraf.

Da die Firma weiterhin in den Ausbau der Investitionsplattform und in die Erweiterung der Teams investieren werde, rechnen die Verantwortlichen allerdings damit, dass die EBITDA-Marge in den "kommenden zwei bis vier Jahren" wieder in Richtung des Zielwerts zurückkommen wird.

NEUE INVESTITIONSPROGRAMME AUFLEGEN

Trotz der Bemühungen, die Erwartungen der Investoren etwas zu dämpfen, berichtete Partners Group von einem Beginn des Jahres "mit einer soliden Kundennachfrage". Die Bandbreite für die erwarteten Kundennachfragen im laufenden Geschäftsjahr bezifferte der Asset Manager - wie bereits im Januar - auf 11 bis 14 Mrd EUR (2017: 13,3 Mrd EUR). Zudem kalkuliere er weiterhin mit Tail-Down-Effekten aus reiferen Programmen sowie möglichen Kapitalabflüssen in Höhe von 4,5 Mrd bis 5,5 Mrd CHF.

Am Aktienmarkt werden die Ergebnisse am Dienstag mit klaren Kursavancen honoriert. Erneut habe Partners Group die bereits sehr hohen Erwartungen der Analysten übertreffen können - was mittlerweile "schon fast zum Ritual gehöre", loben etwa die Analysten der ZKB. Gegen 13 Uhr notieren die Partners Group-Aktien um 3,5% im Plus auf 731,00 CHF und damit nahe dem im Januar erreichten Höchstkurs von 734 CHF.

CGC

Ich sehe heute Erfreuliches hier und poste euch anbei aktuelle News:

Quelle:

https://www.newswire.ca/news-r…artnership-677245293.html

News provided byCanopy Growth Corporation

07:00 ET

SMITHS FALLS, ON and MADRID, March 19, 2018 /CNW/ - Canopy Growth Corporation (TSX: WEED) ("Canopy Growth" or "the Company") is pleased to confirm that it has successfully completed a transfer of 1,500 cannabis clones to its Madrid-based partner, Alcaliber SA ("Alcaliber"), completing the first phase of a partnership entered into by both parties (the "Parties") as announced on September 11, 2017.

[Blocked Image: https://mma.prnewswire.com/media/655581/Canopy_Growth_Corporation_Canopy_Growth_completes_genetics_trans.jpg?w=800]

Healthy cannabis clones have arrived in Spain (CNW Group/Canopy Growth Corporation)

Canopy Growth and Alcaliber enjoy a very strong and committed partnership which will continue to see Alcaliber producing cannabis genetics supplied by Canopy Growth subsidiaries for commercialization purposes.

Canopy Growth also wishes to clarify that, contrary to certain speculation, the Company is not in negotiations to acquire Alcaliber.

"Our view of the European continent mirrors our Canadian expansion strategy," said Bruce Linton, Chairman and CEO, Canopy Growth. "We're diversifying our production capabilities on the continent in anticipation of rapid European market expansion. In addition to a large licenced production footprint in Odense, Denmark we are working closely with our partner Alcaliber to capture market share by scaling supply."

The successful transfer marks the third continent with Canopy Growth genetics growing in soil today.

Here's to Future Growth (not just export) in Europe and beyond.

Presse:

http://www.stockwatch.com/News…aspx?bid=Z-C:WEED-2582814

Canopy completes transfer of 1,500 clones to Alcaliber

2018-03-19 07:47 ET - News Release

Mr. Bruce Linton reports

CANOPY GROWTH COMPLETES GENETICS TRANSFER TO SPAIN AND PROVIDES UPDATE ON SPANISH OPERATIONS AND PARTNERSHIP

Canopy Growth Corp. has successfully completed a transfer of 1,500 cannabis clones to its Madrid-based partner, Alcaliber SA, completing the first phase of a partnership entered into by both parties as announced on Sept. 11, 2017.

Canopy Growth and Alcaliber enjoy a very strong and committed partnership which will continue to see Alcaliber producing cannabis genetics supplied by Canopy Growth subsidiaries for commercialization purposes.

Canopy Growth also wishes to clarify that, contrary to certain speculation, the company is not in negotiations to acquire Alcaliber.

"Our view of the European continent mirrors our Canadian expansion strategy," said Bruce Linton, chairman and chief executive officer, Canopy Growth. "We're diversifying our production capabilities on the continent in anticipation of rapid European market expansion. In addition to a large licensed production footprint in Odense, Denmark, we are working closely with our partner Alcaliber to capture market share by scaling supply."

The successful transfer marks the third continent with Canopy Growth genetics growing in soil today.

About Canopy Growth Corp.

Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and softgel capsule forms.

Canopy Growth has established partnerships with leading sector names including cannabis icon Snoop Dogg, breeding legends DNA Genetics and Green House seeds, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates seven cannabis production sites with over one million square feet of production capacity, including over 500,000 square feet of GMP-certified production space. The company has operations in seven countries across four continents.

We seek Safe Harbor.

© 2018 Canjex Publishing Ltd. All rights reserved.

Termin

Ich danke dir; anbei offiziell noch der Zahlentermin 2017 sowie die Mitteilung betreffend VR, habt ihr vermutlich auch bekommen.

Dear investors,

Partners Group cordially invites you to participate in the presentation of its annual results for the full-year 2017 on 20 March 2018. The presentation will be led by Dr. Peter Wuffli, Chairman of Partners Group’s Board of Directors, André Frei and Christoph Rubeli, Co-Chief Executive Officers, and Philip Sauer, Co-Head Group Finance & Corporate Development.

The event will take place as follows:

Date: Tuesday 20 March 2018

Time: 9.00 am CET – approx. 10.30 am CET

Place: SIX ConventionPoint, Pfingstweidstrasse 110, 8005 Zürich

You may either attend the presentation in person or by dialing in to the conference call. There will also be a playback of the conference call available for 36 hours after the call.

Should you wish to participate, please reply to this email and indicate whether you will attend in person, via the conference call or by accessing the playback. We will provide you with all relevant details closer to the date.

A press release containing the key figures from the annual results will be published together with the full annual report before the presentation, at 7.00 am CET on Tuesday 20 March 2018.

We look forward to hearing from you.

Kind regards,
Philip

Philip Sauer
Co-Head Group Finance & Corporate Development

Partners Group
Zugerstrasse 57
6341 Baar-Zug
Switzerland

T +41 41 784 66 60
F +41 41 784 60 01
philip.sauer@partnersgroup.com
www.partnersgroup.com

Presse:

https://www.finews.ch/news/fin…verwaltungsratspraesident

https://www.moneycab.com/2018/…ls-neuen-vr-praesidenten/

Ich sehe hier grad ein freundliches 'V' im Chart, man kommt hier wieder auf Kurs und am 20. März dürfte ein schönes Q4/Jahresergebnis warten. Dividende Fr. 15.-.

Weiss jemand das diesjährige Ex-Datum?

So eine Börsenklatsche wie vergangene Woche geht auch an den besten Playern nicht spurlos vorbei. Aber wenigstens arbeiten die stets gut.

Emil hat am 02.03.2018 17:41 geschrieben:

Quote

Selector

Meinst du die Schergen von DonaldJ? *dirol*

Nun, wer regiert die Welt - oder glaubt wenigstens, dies zu tun?- Nur, grad ganz doof sind alle anderen ja auch nicht. Psychopathologisch ein interessanter Fall, nur, drum als 'Führer' nicht zu verantworten... *dirol*

Durchhalten

Wohl sollte man sein guten Dividendenpapiere und auch andere, jeweils erfolgreiche Unternehmenspapiere/Aktien, nicht weggeben. Vorsicht vor SL-Limiten, die Leerverkäufer, Hedger, sind unterwegs.- Zu gegebener Zeit > nachkaufen.

Nach den kürzlichen Gewinnmitnahmen und einer sog. Korrektur, könnte man sich hier wieder etwas vorwärts bewegen. Den Bericht habe ich heute noch gesehen, ist nicht übel geschrieben, klingt für mich nur etwas, als wäre jemand krank gewesen *biggrin* war aber nicht, man war hier nur saugut, und nun warten wir auf noch Besseres.

Canopy Growth: Neue Plantage, neues Glück? Hoffnung keimt auf!

Von

Björn Pahlke

-27. Februar 2018

Lieber Leser,

die Canopy Growth-Aktie hat in den vergangenen Tagen einen weiteren Verlust verzeichnen müssen. Dennoch gibt es Hoffnung für die Cannabis-Aktie. Die Lizensierung einer neuen Plantage kam bei den Anlegern gut an und könnte den Kurs nach oben drücken.

Nach einem schwachen Jahresstart sind viele Cannabis-Aktien deutlich gesunken. Auch die Canopy Growth-Aktie verzeichnete einen deutlichen Verlust. Anfang des Jahres stand die Aktie noch über 28 €. Jetzt wird die Aktie bei gerade einmal 17,60 € gehandelt. Auch in der letzten Woche war die Aktie eher schwach. Im Vergleich zur letzten Woche hat sie um rund 1,50 € verloren. Die Aktie ist also weiter auf Korrekturkurs.

Diese Aktie geht steil: US-Aktie vor ver-20-fachung! Der Name der Aktie lautet…

Ende letzter Woche gab das Unternehmen aber die Lizenzierung zur Kultivierung einer neuen Plantage in British Columbia bekannt. Aus eigenen Angaben soll es sich dabei um die weltweit größte lizenzierte Plantage handeln. Durch diese Bekanntmachung sollte sich die Preismacht des Unternehmens nach oben bewegen, worauf die Anleger auch positiv reagierten. Canopy Growth könnte sich dadurch einen Vorteil gegenüber seinen Konkurrenten verschaffen.

Fazit: Die Aktie kann weiter keinen Gewinn markieren. Dennoch ist durch die Lizenzierung einer großen, neuen Plantage wieder Hoffnung aufgekeimt. Canopy Growth könnte den Konkurrenten einen Schritt voraus sein......

Quelle:

https://www.finanztrends.info/…lueck-hoffnung-keimt-auf/

Ach, noch was, für solche die Lust zum Risiko haben:

Globe says Aphria, rivals seen as global leaders

2018-02-26 08:07 ET - Use of Proceeds

See In the News (C-APH) Aphria Inc

The Globe and Mail reports in its Monday, Feb. 26, edition that Colombia is attracting Canadian investment and global attention for its progressive and research-based policies on marijuana. The Globe's guest columnists Alvaro Torres and Matt Murphy write that in Latin America, after Uruguay, the move to legalize medical pot really began in one of the region's largest economies, with the first licences issued in Colombia in 2017. In recent months, medical-cannabis legislation has also passed in Chile, Argentina and Peru, with politicians seeing the growing and cultivation of cannabis for medical purposes as a viable alternative to the illegal drug trade of a generation ago, and a defence against the opioid crisis seen across Canada and the United States. As Canada's new recreational weed laws come into effect later this year, it is fast being recognized as the leader in the sector in Latin America and around the globe with its expertise in market investment, banking, retail, technology, scientific and medical research. With a combined population of more than 640 million, Latin America offers a vast strategic alternative to the U.S. for Canada to use its financial capital in the medical-marijuana industry.

FSLR Q4/2017

FSLR

*dirol* Nun kann man sie wieder zusammenkratzen, wenn man will:

22.02.2018 | 22:55

TEMPE (dpa-AFX) - First Solar, Inc. (FSLR) has raised its 2018 revenue, EPS, and net cash guidance as a result of revised systems project sale timing, increased Series 4 production, the expected sale of 8point3 and other developments. Earnings per share are now projected to be in the range of $1.50 to $1.90, up from prior guidance range of $1.25 to $1.75. Net sales are now expected in a range of $2.45 to $2.65 billion, revised from prior guidance of $2.3 to $2.5 billion.

The company reported a fourth-quarter GAAP loss per share of $4.14. The results included charges of $408 million, or $3.91 per share, from U.S. tax reform. Non-GAAP loss per share was $0.25, for the fourth quarter. Net sales for the fourth quarter were $339 million. The company said its fourth quarter net sales were slightly lower than guidance as a result of certain foreign project sales that are now expected to be recognized in 2018.

Copyright RTT News/dpa-AFX

© 2018 AFX News

https://www.investors.com/news…revenue-beat-on-earnings/

http://www.rttnews.com/2865684…c-q4-earnings-report.aspx

CGC-News

Anbei mal wieder was Erfrischendes zu lesen von heute:

https://www.newswire.ca/news-r…n-manitoba-674278493.html

07:37 ET

SMITHS FALLS, ON, Feb. 16, 2018 /CNW/ - Canopy Growth Corporation (TSX: WEED) ("Canopy Growth" or the "Company") is pleased to announce that it has been conditionally selected by the Government of Manitoba to operate cannabis retail stores in the province after a rigorous and highly competitive RFP process. Canopy Growth, along with its partner Delta 9, is one of four successful candidates chosen to operate a number of retail locations throughout the province. Further details on locations and store quantities will follow as the RFP process is finalized.

Once official, this will mark Canopy Growth's second provincial retail agreement after previously announcing plans to apply to operate four retail stores in the Province of Newfoundland & Labrador. To date, four provinces in Canada have put forward their retail and supply frameworks including New Brunswick, Newfoundland & Labrador, and Prince Edward Island; and all of them have chosen Canopy Growth as a trusted partner and supplier. Just this week, Canopy Growth also entered into a Letter of Intent (LOI) with the province of Quebec to supply up to 12,000 kg of cannabis in that province annually.

"I would like to commend the Government of Manitoba on choosing a competitive retail model that offers access to a variety of new and existing cannabis brands to Manitobans," said Mark Zekulin, President, Canopy Growth. "We look forward to establishing friendly and modern retail spaces that prioritize consumer education and superior customer service, resulting in a safe and positive experience for adult consumers while introducing them to the best brands Canada has to offer including Tweed, Leafs By Snoop, DNA Genetics and a variety of carefully curated independent CraftGrow partners from around the country."

Canopy Growth is dedicated to promoting education and informed understanding of cannabis. Established partnerships with organizations like MADD Canada and Parent Action on Drugs (PAD) support the Company's goal of entering the legalized recreational market in Canada in a responsible manner. With a focus on customer education and retail training, Canopy Growth aims to ensure adult consumers in the Province of Manitoba will enjoy informed, and safe cannabis experiences provided through a welcoming and informative retail experience.

Here's to Future Growth (in Manitoba).

About Tweed
Tweed is a globally recognized cannabis production brand. It has built a large and loyal following by focusing on quality products and meaningful customer relationships. Tweed doesn't just sell cannabis, it facilitates a conversation about a product we've all heard about but haven't met intimately yet. It is approachable and friendly, yet reliable and trusted. As cannabis laws liberalize around the world, Tweed will expand its leading Canadian position around the globe. Learn more at www.tweed.com.

About Canopy Growth Corporation
Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time.

Presse:

https://www.reuters.com/articl…in-province-idUSFWN1Q60QA

Q3-CGC / 2018

Anbei die Zahlen, ist etwas viel, drum s. Link:

https://www.newswire.ca/news-r…-execution-674025453.html

Info:

SMITHS FALLS, ON, Feb. 14, 2018 /CNW/ - Canopy Growth Corporation (TSX: WEED) ("Canopy Growth" or the "Company") today announced that it has signed a letter of intent with the Société des alcools du Québec ("SAQ") to provide the Quebec market with 12,000 kilos of high-quality cannabis annually.

This announcement marks Canopy Growth's fourth and largest supply agreement to-date, following previous agreements with the Provinces of New Brunswick, Newfoundland and Labrador, and Prince Edward Island. Three provinces have now announced supply arrangements with Licensed Producers, all of which include Canopy Growth. The Company now has more supply commitments than any other Licensed Producer in the country.

"We've made major investments in the Province of Québec and feel honoured to be chosen to supply the country's second-largest province, and a region we call home, with our wide variety of cannabis products," said Mark Zekulin, President, Canopy Growth. "Signing this letter of intent with SAQ further establishes our dedication to the region and our level of commitment to providing adult consumers in Québec with safe, high-quality cannabis."

Canopy Growth has established a large presence in Québec with the acquisition of Vert Cannabis in Saint Lucien, Québec, and the recent introduction of Vert Mirabel, a Joint Venture with Les Serres Stéphane Bertrand Inc., a large-scale tomato greenhouse operator in Mirabel, Québec.

https://www.newswire.ca/news-r…-du-quebec-674024343.html

Presse:

REFILE-Canadian weed producer Canopy Growth posts 123 pct jump in 3rd-qtr revenue

Reuters Staff

(Refiles to change date to Feb. 14)

By Nichola Saminather

TORONTO, Feb 14 (Reuters) - Canada’s biggest marijuana producer Canopy Growth said on Wednesday its third-quarter revenue jumped 123 percent to C$21.7 million in the three months ended Dec. 30.

The Smiths Falls, Ontario-based company reported net profit rose to C$11 million, or C$0.01 per share in the three months ended Dec. 30, compared with C$3 million, or C$0.02 a share, a year earlier. The average analyst forecast was for a loss of $7.1 million, or C$0.05 a share.

Reporting By Nichola Saminather Editing by Chizu Nomiyama

Our Standards:The Thomson Reuters Trust Principles.

Hier noch die letzten News (sind von vergangener Woche):

http://www.stockwatch.com/News…aspx?bid=Z-C:WEED-2566437

Also, das wäre abgeschlossen.

Info/Temin Q-Bericht

Kurz-Info:

SMITHS FALLS, ON, Jan. 30, 2018 /CNW/ - Canopy Growth Corporation (TSX: WEED) ("Canopy Growth") will release its financial results for the third quarter fiscal 2018 ended December 31, 2017 on February 14, 2018.

Following the release of its third quarter fiscal 2018 financial results, Canopy Growth will host a conference call and audio webcast with Bruce Linton, CEO and Tim Saunders, CFO at 8:30 AM Eastern Time the same day.

Webcast Information
A live audio webcast will be available at: http://event.on24.com/r.htm?e=…73ED845DDE857FD35673F9872

Calling Information
Toll Free Dial-In Number: 1-888-231-8191
International Dial-In Number (647) 427-7450
Conference ID: 7877468

Replay Information
A replay of the call will be accessible by telephone until 11:59 PM ET on May 14, 2018.
Toll Free Dial-in Number: 1-855-859-2056
Replay Password: 7877468

Quelle:

https://www.newswire.ca/news-r…al-results-671777953.html

Machst du halt mal Pause bis zum 7. Februar. Am 22. Februar ist dann aber Q3 geplant. *smile* *dirol*

CGC

Hier war noch was, das ich euch sagen wollte, aber ich kam nicht dazu.

Die Info ist vom 10. Januar und ich finde sie ganz interessant (der Kurs ist es auch, gerade jetzt):

2018-01-10 09:54 ET

CANOPY RIVERS CLOSES OVERSUBSCRIBED $26 MILLION FINANCING VIA PRIVATE PLACEMENT

Canopy Growth Corp.'s partly owned subsidiary, Canopy Rivers Corp. has closed a non-brokered private placement offering of 23,636,363 Class B common shares at a price of $1.10 per share. Pursuant to the offering, Canopy Rivers raised aggregate gross proceeds of approximately $26-million. Canopy Growth subscribed for 4,673,938 shares for $5,141,331.80.

"Canopy Rivers has efficiently allocated the initial capital and quickly established an attractive portfolio of diversified investments including licensed producers, late-stage applicants, ancillary-product developers and industry-leading brands," says Bruce Linton, chief executive officer of Canopy Growth and chairman of Canopy Rivers.

Founded in April, 2017, Canopy Rivers was formed to complete streaming deals to flow product through Canopy Growth's platform and diversify supply channels to satisfy the needs of Canada's largest group of cannabis customers. As the Canopy Rivers leadership team evaluated the landscape and identified additional deal potential, a more robust business model matured to complement streaming activities. Today, Canopy Rivers has a portfolio of diversified investments and represents a balanced mix of equity, debt, royalty and profit-sharing investment structures.

"Our team has curated a tier one group of complementary but unique investee companies in a short period of time," said Sean McNulty, co-founder of Canopy Rivers. "We have pioneered a series of offtake and strategic support programs and efficiently leveraged the resources of Canopy Growth's cannabis production and distribution platform in a way that creates long-term value for our investors."

Canopy Growth controls the majority voting rights in Canopy Rivers and holds an approximate 30-per-cent-equity stake on a non-diluted basis. The balance of Canopy Rivers shares is held by strategic partners and private investors, including members of both Canopy Growth and Canopy Rivers who participated in this financing round.

"The cannabis investment landscape continues to become more crowded and difficult for investors to track, evaluate and differentiate. Canopy Rivers offers its investors financial exposure to a funnel of domestic and international opportunities, with both private and public companies, in risk-mitigated structures that are typically not prevalent in conventional financial markets. This funnel is filtered, evaluated and scrutinized by a team of financial and legal professionals, and ultimately vetted by the largest and most sophisticated cannabis company in the world. We are in the infancy of this globally emerging industry and our pipeline of opportunities has never been more robust," says Peter Hatziioannou, co-founder of Canopy Rivers.

Proceeds of the private placement will be used to provide growth capital in various forms, including, but not limited to, the purchase of a right to cannabis production, royalty transactions and other strategic investments in or providing financing for companies either licensed to produce cannabis or companies that have applied, or are in the process of applying, for a licence to produce cannabis as well as for working capital and general corporate purposes. Rivers is committed to exclusively investing and supporting firms operating in federally legal jurisdictions.

Eptinger

Einverstanden, obwohl hier heute einige ein Gewinnchen mitgenommen haben, denke ich, es geht doch da endlich wieder aufwärts, sonst schlafen einem die Füsse ein, wenn man hier traden möchte und mehr als ein Up von nur mal kurz $5.- erwartet. Nun aber, die sind entweder weg nun oder steigen wieder ein. Ich schaue den Chart an und sehe ein Preisziel. Wenn ich sechs Jahre retour schaue, na ist wohl nicht ganz 100.-. Aber 80.- balde mal, das könnte schon gut drinliegen. Wir nehmen auch mehr. Dann bin ich noch gespannt wie das hier ausgeht: *smile* *dirol*

https://www.benzinga.com/media…s-activity-in-first-solar

On CNBC's "Options Action", Mike Khouw said First Solar, Inc. FSLR 4.32% saw four times the average daily call options volume Thursday. He added that options traders were buying the January 75 calls in the name.

Around 4,000 contracts were traded during the session and they paid $2 for them. The trade breaks even at $77 or 0.96 percent above the current stock price. Khouw explained that buyers could be expecting that President Trump is going to announce protectionist policies for the solar industry next week.